Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Clazosentan Disodium
2. Clazosentan Disodium Salt
3. Clazosentan Sodium [jan]
4. Clazosentan Disodium Salt [mi]
5. 0l77pk62l1
6. 503271-02-1
7. 2-pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1h-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-methyl-, Disodium Salt
8. Unii-0l77pk62l1
9. Dtxsid10198341
10. Q27236935
| Molecular Weight | 621.5 g/mol |
|---|---|
| Molecular Formula | C25H21N9Na2O6S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 11 |
| Exact Mass | 621.11308916 g/mol |
| Monoisotopic Mass | 621.11308916 g/mol |
| Topological Polar Surface Area | 183 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 911 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Drugs in Development
Details:
Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: Pivlaz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: HANDOK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 14, 2024
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : HANDOK
Deal Size : Undisclosed
Deal Type : Agreement
Nxera Pharma Announces Exclusive Supply Agreement with Handok for Pivlaz™
Details : Handok is responsible for commercialization of Pivlaz (clazosentan sodium), approved in South Korea for preventing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Brand Name : Pivlaz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 14, 2024
Details:
South Korea approved PIVLAZ™ (clazosentan sodium), an ETAR antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: Pivlaz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
Details : South Korea approved PIVLAZ™ (clazosentan sodium), an ETAR antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
Brand Name : Pivlaz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2023
Details:
Through the acquisition, Sosei also gains assignment of Pivlaz (clazosentan), for the treatment of cerebral vasospasm, and license rights to daridorexant in the Asia Pacific (ex-China) region.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: Pivlaz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sosei Heptares
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sosei Heptares
Deal Size : Undisclosed
Deal Type : Acquisition
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Acceler...
Details : Through the acquisition, Sosei also gains assignment of Pivlaz (clazosentan), for the treatment of cerebral vasospasm, and license rights to daridorexant in the Asia Pacific (ex-China) region.
Brand Name : Pivlaz
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2023
Details:
ACT-108475 (clazosentan) is a fast-acting, endothelin A (ETA) receptor antagonist, that Idorsia has developed as a continuous intravenous infusion for the prevention of clinical deterioration due to delayed cerebral ischemia (DCI) in patients following aSAH.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: ACT-108475
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ACT-108475 (clazosentan) is a fast-acting, endothelin A (ETA) receptor antagonist, that Idorsia has developed as a continuous intravenous infusion for the prevention of clinical deterioration due to delayed cerebral ischemia (DCI) in patients following a...
Brand Name : ACT-108475
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 06, 2023
Details:
PIVLAZ (clazosentan sodium), a selective endothelin A receptor antagonist received Japanese PMDA approval on the basis of statistically significant result from the Japanese Phase 3 program for the prevention of cerebral vasospasm after subarachnoid hemorrhage treatment.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: Pivlaz
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Idorsia Receives Japanese PMDA Approval of PIVLAZ (clazosentan sodium) 150 mg
Details : PIVLAZ (clazosentan sodium), a selective endothelin A receptor antagonist received Japanese PMDA approval on the basis of statistically significant result from the Japanese Phase 3 program for the prevention of cerebral vasospasm after subarachnoid hemor...
Brand Name : Pivlaz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 20, 2022
Details:
A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan administered by continuous intravenous infusion significantly reduced vasospasm and vasospasm-related morbidity and mortality events.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: ACT-108475
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Idorsia Submits NDA for Clazosentan to Japanese PMDA
Details : A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan administered by continuous intravenous infusion significantly reduced vasospasm and vasospasm-related morbidity and mortality events.
Brand Name : ACT-108475
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2021
Details:
Both studies demonstrated that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies).
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Brand Name: ACT-108475
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Idorsia Announces Positive Results of the Two Japanese Registration Studies with Clazosentan
Details : Both studies demonstrated that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies).
Brand Name : ACT-108475
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
16 Apr 2024
// BIOSPECTRUM ASIA
https://www.biospectrumasia.com/news/25/24084/nxera-pharma-inks-deal-with-handok-to-distribute-pivlaz-in-south-korea.html
14 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/14/2862478/0/en/Nxera-Pharma-Announces-Exclusive-Supply-and-Distribution-Agreement-with-Handok-for-PIVLAZ-in-South-Korea.html
07 Dec 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/12/07/2792220/0/en/Sosei-Group-Announces-Marketing-Approval-for-PIVLAZ-clazosentan-sodium-150-mg-in-South-Korea.html
07 Feb 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/02/06/2601762/0/de/Idorsia-announces-th[…]patients-following-aneurysmal-subarachnoid-hemorrhage.html
20 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/20/2425136/0/de/PIVLAZ-clazosentan-Idorsia-s-first-commercial-product-now-available-for-patients-in-Japan.html
04 Apr 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/04/04/2415246/0/de/The-Journal-of-Neurosurgery-reports-impact-of-clazosentan-on-cerebral-vasospasm-related-morbidity-and-all-cause-mortality-after-aneurysmal-subarachnoid-hemorrhage.html
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Share 
Comment (7)
